

**THE CLINICAL PHARMACOLOGY OF
METHADONE INDUCTION**

Erin Brooke Morton, BBiotech(Hons)

Discipline of Pharmacology

School of Medical Sciences

(Faculty of Health Sciences)

University of Adelaide

January 2007

A thesis submitted for the degree of Doctor of Philosophy

Table of Contents

List of Chapters.....	ii
List of Tables	xiv
List of Figures.....	xviii
List of Equations	xxi
List of Appendices.....	xxi
Abstract.....	xxii
Declaration	xxv
Acknowledgements	xxvi
Publications and presentations in support of this thesis	xxviii
Additional publications and presentations associated with the work contained in this thesis	xxviii
Abbreviations, prefixes and symbols	xxix

1. Methadone Pharmacology: A Review of the Literature; Hypotheses & Aims of the Project	1
1.1. Opioid Pharmacology	1
1.1.1. Historical use of plant-derived medicines.	1
1.1.2. Opium discovery and therapeutic use	2
1.1.3. Opioid receptors	2
1.1.3.1. Binding by the μ Opioid Receptor (MOP)	3
1.1.3.2. Regulation of the μ Opioid Receptor (MOP)	6
1.1.3.3. μ Opioid Receptor (MOP), and its encoding gene (<i>OPRM1</i>)	7
1.1.4. Physiological Responses to Activation of the μ Opioid Receptor (MOP)	8
1.1.5. Heroin synthesis, addiction, and current problems	9
1.2. Dependence and addiction.....	10
1.3. Substitution Treatments.....	11
1.4. Methadone Maintenance Treatment.....	12
1.4.1. History.....	12
1.4.2. Objectives.....	12
1.4.3. Recruitment and Retention.....	13
1.5. Methadone Pharmacology in Relation to MMT.....	13
1.5.1. Physiological Reactions to MMT.....	14
1.5.2. Pharmacokinetic/Pharmacodynamic Relationships	14
1.5.3. Withdrawal	17
1.5.4. Tolerance	18
1.5.5. Cross-tolerance.....	19
1.5.6. Current Methodology for MMT	20
1.5.6.1. Routes of Methadone Administration	20

1.5.6.2.	Chronic Dosing in MMT to Target a Narrow Plasma Concentration Range	20
1.5.6.3.	Single vs Divided Daily Dose	21
1.5.6.4.	MMT Locale: Hospital/Clinic versus Private Practice.	22
1.5.7.	Risks of MMT	23
1.5.7.1.	Constipation	23
1.5.7.2.	Nausea and Vomiting	24
1.5.7.3.	Drowsiness, Confusion, and Mood State	24
1.5.7.4.	Hyperalgesia.....	25
1.5.7.5.	Respiratory depression, toxicity and death	26
1.5.8.	Starting Doses in MMT.....	30
1.5.9.	Factors that can Change the Outcome of MMT	32
1.5.9.1.	Social environment	32
1.5.9.2.	Therapy environment	32
1.5.9.3.	Family history	33
1.5.9.4.	Genetic factors (pharmacogenetics).....	34
1.5.10.	Continued heroin use during MMT.....	34
1.6.	Methadone	35
1.6.1.	Methadone Chemistry	35
1.6.1.1.	Physicochemical Properties and Australian Availability of Methadone	35
1.6.1.2.	Stereoisomers of Methadone.....	36
1.7.	Pharmacokinetics of Methadone in the Human Body.....	37
1.7.1.	Methadone Pharmacokinetics in Acute and Chronic Dosing	37
1.7.1.1.	Stable Isotope Utilisation for Pharmacokinetic Studies.....	46
1.7.2.	Pharmacokinetic Parameters and Causes of Change	48
1.7.2.1.	Clearance via Metabolism.....	48

1.7.2.1.1.	CYP3A4.....	49
1.7.2.1.2.	Auto-induction of CYP3A4 metabolism	50
1.7.2.1.3.	Methods for Measuring CYP3A4 Activity.....	54
1.7.2.1.3.1.	Erythromycin Breath Test (EBT)	55
1.7.2.1.4.	<i>CYP2D6</i> and genotyping	56
1.7.2.2.	Renal Clearance.....	57
1.7.2.3.	Bioavailability	58
1.7.2.4.	Volume of Distribution	58
1.7.2.4.1.	Protein binding by α -1-acid glycoprotein (AAG)	59
1.7.2.5.	Half-life	61
1.7.2.6.	Stereoselective differences	61
1.7.3.	Factors that may alter Methadone Pharmacokinetics.....	66
1.7.3.1.	P-glycoprotein (encoded by the <i>MDR1</i> / <i>ABCB1</i> gene).....	66
1.7.3.2.	Pregnancy and lactation	67
1.7.3.3.	Liver, renal, and respiratory diseases	67
1.7.3.4.	Drug Interactions.....	69
1.8.	Summary and Conclusions from Existing Literature	70
1.9.	Overview and Significance of the Current Research	71
1.9.1.	Hypotheses	73
1.9.2.	Aims and Objectives	74
2.	Study Details, Subject Recruitment, Clinical Procedure, and Subject Characteristics	75
2.1.	Study Design	75
2.2.	Study Overview	75
2.3.	Recruitment	76

2.3.1.	Centres Involved	76
2.3.2.	Recruitment Procedure.....	78
2.3.3.	Confidential Codes for Subjects.....	78
2.3.4.	Inclusion/Exclusion Criteria and Adherence to the Protocol.....	79
2.3.4.1.	Age, Gender, Suitability, and Consent.....	79
2.3.4.2.	Anomalous Methadone Intake in One Subject.....	79
2.3.4.3.	Pregnancy and Liver Function	80
2.3.4.4.	Mental Health.....	80
2.3.4.5.	Protocol Violations leading to Exclusion.....	81
2.3.5.	Reasons for Non-completion of the Studies.....	82
2.3.5.1.	Subjects that failed the criteria.....	82
2.3.5.2.	Subjects that withdrew from the study.....	82
2.4.	Study Protocol	82
2.4.1.	General	82
2.4.2.	Study A: Pharmacokinetics and pharmacodynamics of methadone from the time of induction to stable maintenance.....	84
2.4.3.	Study B: Predicting Methadone Stabilisation Dose	88
2.5.	Subject Characteristics	89
3.	Experimental Methods.....	92
3.1.	Chemicals and Reagents.....	94
3.2.	LC-MS Assay for Quantification of ² H ₆ (d6) and ² H ₀ (d0) R- and S-methadone Concentrations in the Plasma Samples of MMT Subjects	95
3.2.1.	Instrumentation and Chromatography Conditions	95
3.2.2.	Sample Preparation	96
3.2.3.	Assay Calibration, Quality Control Samples, and Validation.....	96

3.2.4.	Data Corrections.....	97
3.2.5.	Data Analysis	98
3.2.6.	Validation Results and Discussion.....	101
3.2.7.	LC-MS Difficulties.....	104
3.2.8.	Assay of subjects' samples.....	104
3.2.9.	Pharmacokinetic Analyses	105
3.2.10.	Statistical Analyses.....	106
3.2.11.	Comparison to UV-HPLC	107
3.3.	HPLC with UV Chromatography for Plasma Methadone Concentrations in MMT subjects during Days 5-14 and 44-49 of chronic daily oral dosing	107
3.3.1.	HPLC Instrumentation and Chromatography Conditions	107
3.3.2.	Sample Preparation.....	108
3.3.3.	Assay Calibration, Quality Control Samples, and Validation.....	108
3.3.4.	Data analysis.....	109
3.3.5.	Validation Results and Discussion	112
3.3.6.	Assay of subjects' samples.....	113
3.4.	Morphine Concentrations	114
3.4.1.	Hair Samples	114
3.4.1.1.	Procedures	114
3.4.1.2.	Data Analysis	114
3.4.2.	Plasma Morphine Concentrations	115
3.4.2.1.	Instrumentation and Chromatography Conditions	115
3.4.2.2.	Sample Preparation	115
3.4.2.3.	Assay trouble-shooting.....	116
3.4.3.	Assay Calibration, Quality Control Samples, and Validation.....	117
3.4.4.	Data analysis.....	117

3.4.5.	Validation Results and Discussion.....	120
3.4.6.	Assay of subjects' samples.....	121
3.5.	Estimation of Concurrent Heroin Use during MMT	121
3.5.1.	Statistical Analyses	122
3.5.2.	Statistical Analyses using Multiple Linear Regression.....	122
3.5.3.	Selection of Independent Variables and Subject Groups	123
3.6.	Erythromycin Breath Test (EBT).....	124
3.6.1.	Equipment	124
3.6.2.	Procedure.....	126
3.6.2.1.	Subjects	126
3.6.2.2.	Vials	126
3.6.3.	Quantification of ¹⁴ CO ₂	127
3.6.4.	Validation of EBT	127
3.6.5.	Data analysis	128
3.6.6.	Statistical Analysis	130
3.7.	Plasma AAG Concentration Measurement	131
3.7.1.	Instrumentation and Conditions	131
3.7.2.	Sample Preparation	131
3.7.3.	Assay Calibration, Quality Controls, and Validation.....	131
3.7.4.	Data analysis	131
3.7.5.	Validation Results and Discussion.....	132
3.7.6.	Assay of subject samples	132
3.8.	Pharmacodynamics.....	133
3.8.1.	Methadone Symptoms Checklist as a measure of withdrawal.....	133
3.8.2.	Respiratory rates and Oxygen Saturation.....	135
3.8.3.	Data analyses.....	136

3.8.3.1.	Regression analyses.....	136
3.8.3.1.1.	Total Plasma Methadone Concentrations	137
3.8.3.1.2.	Pharmacodynamic Effects of Withdrawal Symptoms, Respiratory Rate and Blood Oxygen Saturation, and Plasma Methadone Concentration-Effect Relationships	137
3.8.3.2.	Power of the studies	137
4.	Pharmacokinetics of Methadone during Induction and Stabilisation of MMT .	139
4.1.	Introduction	139
4.2.	Results: Plasma d6-R- and d6-S-Methadone Concentrations as Measured by LC-MS.....	141
4.3.	Pharmacokinetics of IV d6-methadone: Calculated from LC-MS Results	143
4.4.	Plasma AAG Concentrations on Day 1 and Day 40 for 24 MMT subjects	150
4.5.	Discussion.....	153
4.5.1.	Pharmacokinetics.....	153
4.5.1.1.	Methadone Pharmacokinetics and differences in routes of administration.....	153
4.5.1.2.	Stereospecific methadone pharmacokinetics	155
4.5.1.3.	Changes in Methadone Clearance in this Study.....	157
4.5.1.3.1.	Presence of illicit drugs.....	158
4.5.1.4.	A Reported Change in Half-Life between Methadone Isotopes	160
4.5.1.5.	A Study Comparison of Methadone Pharmacokinetic Parameter Changes	161
4.5.1.6.	Summary	165

5.	Relationship between Cytochrome P450 CYP3A4 Activity as Measured by the EBT and Changes in Methadone Clearance during Induction and Stabilisation	167
5.1.	Introduction	167
5.2.	Results	169
5.2.1.	Sampling	169
5.2.2.	Modelling of Data	169
5.2.3.	EBT Parameters	171
5.3.	Correlation: Relationship between <i>in vivo</i> Hepatic CYP3A4 Activity and Methadone Enantiomer Clearance	174
5.4.	Discussion	178
5.4.1.	EBT in this study	178
5.4.2.	CYP3A4 activity and Methadone Pharmacokinetics	179
5.4.3.	CYP3A4 activity in general	180
5.4.3.1.	CYP3A4 activity and Benzodiazepines and Liver Function.....	180
5.4.3.2.	CYP3A4 activity and nutritional status	181
5.4.4.	EBT in general	181
5.4.4.1.	Comparisons with the EBT in the literature.....	181
5.4.4.2.	Potential Limitations	184
5.4.4.3.	EBT Advantages	186
5.4.5.	Summary	187
6.	Pharmacodynamics and Total Plasma Methadone Concentrations during Induction and Stabilisation of MMT	188
6.1.	Introduction	188
6.2.	Methodological Findings.....	189

6.2.1.	HPLC with UV chromatography and Total (d0 + d6) Plasma Methadone Concentrations.....	189
6.2.2.	Accuracy and Reproducibility of the HPLC with UV Chromatography Assay	190
6.2.3.	Results and Analyses: Plasma Methadone Concentrations and Linear Regression against Dose.....	191
6.2.4.	Plasma Methadone Concentrations and Multiple Linear Regression	198
6.2.5.	Discussion of Methadone Dose and Plasma Methadone Concentrations	199
6.2.5.1.	Plasma methadone concentrations during MMT	200
6.2.5.2.	Plasma methadone concentrations in this study.....	200
6.3.	Pharmacodynamic Effects	202
6.3.1.	Withdrawal Symptoms measured by the Methadone Symptoms Checklist.	202
6.3.1.1.	Categorical Withdrawal Score Results.....	203
6.3.1.2.	Withdrawal Score and MMT Details	206
6.3.1.3.	MSC-Categorical Withdrawal Score and Methadone Concentration-Effect Relationship.....	207
6.3.1.4.	Discussion of Withdrawal Symptoms during MMT	211
6.3.1.4.1.	Withdrawal Scores from this study and their relationship with plasma methadone concentrations	211
6.3.1.4.2.	Summary	213
6.3.2.	Respiratory rate	213
6.3.2.1.	Respiratory rate Results	214
6.3.2.2.	Blood Oxygen Saturation Results	217
6.3.2.3.	Clinically Significant Respiratory Depression.....	220
6.3.2.4.	Respiratory rate and MMT Details.....	221
6.3.2.5.	Blood Oxygen Saturation and MMT Details	222

6.3.2.6.	Respiratory Function and Methadone Concentration-Effect Relationships	224
6.3.2.7.	Discussion of Respiratory Function during MMT	234
6.3.2.7.1.	Respiratory function in general	234
6.3.2.7.2.	Respiratory function in relation to MMT	234
6.3.2.7.3.	Respiratory function correlations with plasma methadone concentrations	236
6.3.2.7.4.	Respiratory function and chronic vs acute opioid treatment in other studies	238
6.3.2.7.5.	Summary	239
6.3.3.	Discussion of all Pharmacodynamics during MMT	240
7.	Continued Heroin/Morphine Use during MMT	242
7.1.	Introduction	242
7.2.	Heroin/Morphine Results	242
7.2.1.	Prior to MMT Commencement: Self-Report, Urine, and Hair Sample Analysis	243
7.2.2.	Morphine Assay Performance	247
7.2.3.	Plasma Morphine Concentrations	248
7.2.4.	Comparison of Plasma Morphine Concentrations with Self-Report and Urinalysis	251
7.3.	Continued Heroin Use as a Function of Prior Use, Methadone Dose, and Plasma Methadone Concentrations	252
7.4.	Results of Multiple Linear Regression Analyses	253
7.5.	Discussion	257
7.5.1.	Drug use prior to MMT	257

7.5.2.	Methadone data and continued drug use during MMT	258
7.5.3.	Prediction of continued heroin or morphine use in 10 subjects during MMT (Study A)	259
7.5.4.	Predictions of continued heroin or morphine use in 14 or 24 MMT subjects (Studies A and B)	260
7.5.4.1.	Study protocol comparison.....	262
7.5.5.	Summary	262
8.	Discussion	265
8.1.	Subject Retention and Representation of the MMT Population.....	265
8.2.	Project Findings in Relation to the Project Aims	266
8.3.	Implications of my Results in Regards to MMT	269
8.3.1.	Clearance Differences only between Methadone Isomers	269
8.3.2.	No CYP450 3A4 Activity Correlation with Methadone Clearance.....	271
8.3.3.	Characterisation of MMT Induction Phase Pharmacodynamics.....	272
8.3.4.	Continued Opioid Use during MMT	275
8.3.5.	Study Limitations	277
8.4.	What these implications mean to MMT overall.....	278
8.5.	Summary and Conclusions.....	279
	Appendices.....	280
	Appendix 1: Information for Clinics and Clients.....	280
	Appendix 1-1: Poster for Studies A and B	280
	Appendix 1-2: Information sheet for Study A Subjects	281
	Appendix 1-3: Consent Form for Study A Subjects.....	286
	Appendix 1-4: Information Sheet for Study B Subjects.....	287
	Appendix 1-5: Consent form for Study B Subjects.....	291

Appendix 1-6: Project Summary Sheet for Clinic Staff Use.....	292
Appendix 2: Paperwork for Client Files	293
Appendix 2-1: Case Report Form for Day 1 and Day 40 of Study A	293
Appendix 2-2: Case Report Form for Days 2-14 and Days 41-49 of Study A	294
Appendix 2-3: Case Report Form for Day 1 and Day 40 of Study B	295
Appendix 2-4: Pharmacodynamics Notes Sheet	296
Appendix 2-5: Profile of Mood States Questionnaire	297
Appendix 2-6: Methadone Symptoms Checklist.....	298
Appendix 3: Documentation for Experimental Work	300
Appendix 3-1: LC-MS Methadone Assay Checklist.....	300
Appendix 3-2: LC-MS Methadone Assay Sample Sheet.....	301
Appendix 3-3: LC-MS Methadone Assay Run Sheet	302
Appendix 3-4: HPLC Methadone Assay Checklist.....	303
Appendix 3-5: HPLC Methadone Assay Sample Sheet.....	304
Appendix 3-6: HPLC Methadone Assay Run Sheet	305
Appendix 3-7: Erythromycin Injection Preparation Instructions for RAH Pharmacy	306
Appendix 3-8: Erythromycin Validation Information Sheet.....	307
Appendix 3-9: EBT Validation Report Form.....	309
Appendix 3-10: Morphine Assay Checklist	310
Appendix 3-11: Morphine Assay Sample Sheet	311
Appendix 3-12: Morphine Assay Run Sheet.....	312
Appendix 4: An Additional Publication Associated with the Work Contained in this Thesis.....	313
Bibliography	321

List of Tables

Table 1-1: Summary of pharmacokinetic parameters (racemic) of intravenously administered methadone reported in the literature.....	39
Table 1-2: Summary of pharmacokinetic parameters (racemic) of orally administered methadone reported in the literature.	41
Table 1-3: Summary of pharmacokinetic parameters of methadone enantiomers reported in the literature	62
Table 2-1: Recruitment of Subjects at MMT Centres.....	77
Table 2-2: Sampling schedules for Study A and Study B.....	83
Table 2-3: Study A Subject Demographics.....	89
Table 2-4: Study B Subject Demographics.....	90
Table 2-5: Demographics of the Total Subject Population.....	91
Table 3-1: Subjects' samples (D* = Day * of MMT) tested by LC-MS for plasma methadone concentrations.....	93
Table 3-2: Intra-assay validation of plasma d0 and d6 R- and S-methadone concentrations by the LC-MS assay, using the LOQ and QCs from the large validation assay	102
Table 3-3: Inter-assay validation of plasma d0 and d6 R- and S-methadone concentrations by the LC-MS assay, using the LOQ and QCs from 3 validation assays performed on separate days.....	103
Table 3-4: Intra-assay validation data for the HPLC-UV assay for plasma R- and S-methadone concentrations using the LOQ and QCs from the large validation assay	112
Table 3-5: Inter-assay validation data for the HPLC-UV assay for plasma R- and S-methadone concentrations using the LOQ and QCs from 3 validation assays performed on separate days.....	113

Table 3-6: Intra-assay validation data for the plasma morphine concentration assay using the QCs and two lowest standards from the large validation assay	120
Table 3-7: Inter-assay validation data for the plasma morphine concentration assay using the QCs and two lowest standards from both validation assays	120
Table 3-8: Intra-assay validation data of the plasma AAG concentration radioimmunoassay in a NOR-Partigen [®] plate	132
Table 4-1: Ongoing inter-assay accuracy, precision, r^2 value and slope for assays (n = 11) of plasma d0 and d6 R- and S-methadone concentrations in subjects' samples	142
Table 4-2: Individual pharmacokinetic parameters for R-, S-, and rac-methadone during induction and steady state phases of MMT following IV-dose of 5 mg d6-methadone in 10 Study A subjects	147
Table 4-3: Comparison between R- and S-methadone pharmacokinetic parameters during induction and steady state phases of MMT in 10 subjects after IV-dose of 5 mg d6-methadone.....	149
Table 4-4: Ongoing inter-assay accuracy and precision for assays (n = 8) of plasma AAG concentrations in subjects' samples.....	150
Table 4-5: Individual plasma AAG concentrations (mg/dl) in 10 Study A subjects on Day 1 and Day 40 of MMT	151
Table 4-6: Individual plasma AAG concentrations (mg/dl) in 14 Study B subjects on Day 1 and Day 40 of MMT	151
Table 5-1: Erythromycin Breath Test parameters in 24 Subjects on a) Day 1 and b) Day 40 of MMT.....	172
Table 5-2: Comparison of Day 1 and Day 40 Erythromycin Breath Test parameters in 24 MMT subjects	173
Table 5-3: Correlations between erythromycin clearance and R-, S-, and rac-methadone clearances on Day 1 and Day 40 of MMT in 10 Study A subjects.....	176

Table 5-4: Correlations between EBT parameter CER _{20min} and R-, S-, and rac-methadone clearances on Day 1 and Day 40 of MMT in 10 Study A subjects.....	176
Table 5-5: Correlations between EBT parameter T _{max} and R-, S-, and rac-methadone clearances on Day 1 and Day 40 of MMT in 10 Study A subjects.....	177
Table 5-6: Erythromycin, R-, S-, and rac-methadone clearance change (%) from Day 1 to Day 40 of MMT in 10 Study A subjects.....	177
Table 5-7: Correlations between percentage and direction (positive or negative) of erythromycin clearance change and R-, S-, and rac-methadone clearance changes in 10 Study A subjects during MMT.....	178
Table 6-1: Ongoing inter-assay accuracy, precision, r ² value and slope for HPLC with UV chromatography assays (n = 17) of plasma R- and S-methadone concentrations in subjects' samples.....	191
Table 6-2: Regression analysis of day of MMT, methadone dose (mg), and time since dose (h), as predictors of racemic plasma methadone concentrations (ng/ml) in 10 Study A subjects.....	199
Table 6-3: Regression analysis of day of MMT, methadone dose (mg), and time since dose (h), as predictors of categorical withdrawal scores (0-16) in 10 Study A subjects.....	206
Table 7-1: Percentage of a) Study A subjects, b) Study B subjects, and c) total subjects using illicit drugs prior to Day 1 (Day 1) and between Day 1 and Day 40 (Day 40), as measured by self-report and urinalysis.....	244
Table 7-2: Day 1 hair sample analysis results.....	246
Table 7-3: Ongoing inter-assay accuracy, precision, r ² value and slope for assays (n = 8) of plasma morphine in subjects' samples.....	248
Table 7-4: Plasma morphine concentrations for 10 Study A subjects on Days 1-14 and 40-49 of MMT.....	249

Table 7-5: Analysis of Variance (2-way) of median plasma morphine concentrations in 10 Study A subjects during induction and steady state phases of MMT	250
Table 7-6: Regression analyses of [prior drug use (Day 1 hair morphine concentration, hair monoacetylmorphine (MAM) concentration, and hair heroin concentration (ng/mg)), mean methadone dose (mg), and mean plasma R-, S-, and rac-methadone concentration (ng/ml)], as predictors of continued opioid use during MMT as expressed by median plasma morphine concentration (ng/ml) in (1) 10 Study A subjects, (2) 14 non-incarcerated subjects, and (3) 24 Study A and Study B subjects.	254
Table 7-7: Regression analyses of prior drug use (Day 1 hair morphine concentration (ng/mg)), and mean plasma R-methadone concentration (ng/ml), as predictors of continued opioid use during MMT, expressed by median plasma morphine concentration (ng/ml) in (1) 10 Study A subjects, (2) 14 non-incarcerated subjects, and (3) 24 Study A and Study B subjects.	255
Table 7-8: Regression analyses of prior drug use (Day 1 hair morphine concentration and hair monoacetylmorphine (MAM) concentration (ng/mg)), and mean plasma rac-methadone concentration (ng/ml), as predictors of continued opioid use during MMT as expressed by median plasma morphine concentration (ng/ml) in 24 Study A and Study B subjects.....	256
Table 7-9: Regression analyses of prior drug use (Day 1 hair morphine concentration (ng/mg)), as a predictor of continued opioid use during MMT as expressed by median plasma morphine concentration (ng/ml) in (1) 10 Study A subjects, (2) 14 non-incarcerated subjects, and (3) 24 Study A and Study B subjects.	257

List of Figures

Figure 1-1: Phases of μ opioid receptor (MOP) activation.....	4
Figure 1-2: Timeline of μ opioid receptor (MOP) activation represented on log scale.....	5
Figure 1-3: Hyperexcitability and enhanced transmitter release during opioid withdrawal..	17
Figure 1-4: Chemical Structure of Methadone with the chiral atom marked with an asterisk	35
Figure 1-5: Methadone Hydrochloride with stable-labels of ($^2\text{H}_6$)-methadone hydrochloride indicated in bold type, and the chiral carbon identified by an asterisk	47
Figure 1-6: Methadone and metabolites EDDP and EMDP	49
Figure 1-7: Increase in plasma methadone concentration over time, predicted from Population Pharmacokinetic analysis of single dose and steady-state data.	52
Figure 3-1: Representative LC-MS chromatograms of a) drug-free plasma sample and b) subject plasma sample containing both unlabelled and labelled methadone..	99
Figure 3-2: Representative HPLC chromatograms of a) a drug-free plasma sample and b) a subject plasma sample.....	110
Figure 3-3: Representative Coulochem system chromatograms of an a) drug-free plasma sample and a b) subject plasma sample.....	118
Figure 3-4: Urea breath test device with mouthpiece and drinking straw with alkaline trapping solution.	125
Figure 4-1: Mean (\pm SEM) plasma R- and S- $^2\text{H}_6$ -methadone concentrations after a 5 mg IV dose in 10 Study A subjects during a) induction and b) steady state phase of MMT	144
Figure 4-2: Changes in systemic plasma R- and S-methadone clearances (L/h) between induction and steady state phases of MMT in 10 Study A subjects (P = 0.41 and 0.37, respectively)	149
Figure 4-3: Plasma AAG concentrations (mg/dl) on Day 1 and Day 40 of MMT for 24 subjects.....	152

Figure 5-1: CER profiles of a) the volunteer, and b) a representative subject on Day 1, and c) Day 40 of MMT, following a 4 μ Ci IV dose of 14 C-erythromycin	170
Figure 5-2: Changes in erythromycin clearance from Day 1 to Day 40 of MMT (n = 24 subjects).....	172
Figure 5-3: Correlations between erythromycin clearance (L/h) and methadone clearance (L/h) in 10 Study A MMT subjects:	175
Figure 5-4: Correlations between CER _{20min} (% dose/min) and methadone clearance (L/h) in 10 Study A MMT subjects:.....	175
Figure 5-5: Correlations between T _{max} (min) and methadone clearance (L/h) in 10 Study A MMT subjects:	176
Figure 6-1: Methadone dose (mg) changes during MMT in a) 10 Study A subjects and b) 14 Study B subjects	192
Figure 6-2: Total Day 1 and Day 40 methadone doses in 24 MMT Subjects.	193
Figure 6-3: Correlations (with 95 % CI) between mean Study A methadone dose (mg) and peak and trough plasma methadone concentrations (ng/ml) on 14 days of MMT (Day 1 to 14), where each point represents a single day	194
Figure 6-4: Correlations (with 95 % CI) between individual Study A Day 40 methadone dose (mg) and peak and trough plasma a) R-, b) S-, and c) rac-methadone concentrations (ng/ml)	195
Figure 6-5: Mean plasma methadone concentrations (ng/ml) during MMT for Study A subjects.....	197
Figure 6-6: Withdrawal symptom scores (Mean \pm SEM) at time of trough and peak R- Methadone Concentrations in 10 Study A MMT subjects (maximum score = 16)	204
Figure 6-7: Pre- and post-dose withdrawal symptom score (0-16) in 24 subjects on Day 1 and Day 40 of MMT.	205

Figure 6-8: Concentration-effect relationships between plasma R-methadone concentration (ng/ml) and MSC categorical withdrawal symptom score.....	208
Figure 6-9: Plasma R-methadone concentrations and withdrawal scores (0-16) per day of induction phase of MMT in 10 Study A subjects	210
Figure 6-10: Respiratory rates (mean \pm SEM) at time of trough and peak plasma R-methadone concentrations in 10 Study A subjects during MMT.....	215
Figure 6-11: Pre- and post-dose respiratory rates (breaths/min) in 24 subjects (Study A and Study B) on Day 1 and Day 40 of MMT.	216
Figure 6-12: Blood oxygen saturation (mean \pm SEM) at time of trough and peak plasma R-methadone concentrations in 10 Study A subjects.....	218
Figure 6-13: Pre- and post-dose blood oxygen saturation (%) in 24 subjects (Study A and Study B) on Day 1 and Day 40 of MMT.	219
Figure 6-14: Concentration-effect relationships between plasma R-methadone concentration (ng/ml) and respiratory rate (breaths/min).	225
Figure 6-15: Concentration-effect relationships between plasma R-methadone concentration (ng/ml) and blood oxygen saturation (%).	227
Figure 6-16: Concentration-effect relationships between peak plasma R-methadone concentration (ng/ml) and respiratory rate (breaths/min).	230
Figure 6-17: Concentration-effect relationships between peak plasma R-methadone concentration (ng/ml) and blood oxygen saturation (%).	231
Figure 6-18: Plasma R-methadone concentrations (ng/ml) and respiratory rate (breaths/min) at times of trough and peak sampling per day of induction phase of MMT in 10 Study A subjects.....	232
Figure 6-19: Plasma R-methadone concentrations (ng/ml) and blood oxygen saturation (%) at times of trough and peak sampling per day per day of induction phase of MMT in 10 Study A subjects	233

Figure 7-1: Median plasma morphine concentration and percentage of Study A subjects testing positive per day of MMT	251
--	-----

List of Equations

Equation 3-1:.....	106
Equation 3-2:.....	106
Equation 3-3:.....	106
Equation 3-4:.....	106
Equation 3-5:.....	128
Equation 3-6:.....	128
Equation 3-7:.....	129

List of Appendices

Appendix 1: Information for Clinics and Clients	280
Appendix 2: Paperwork for Client Files.....	293
Appendix 3: Documentation for Experimental Work.....	300
Appendix 4: An Additional Publication Associated with the Work Contained in this Thesis.....	313

Abstract

- Methadone is the foremost, long-standing pharmacological treatment for opioid addiction. It has been shown to have considerable cost benefit to the community and to decrease mortality. Despite methadone's decades-long use, much is still unknown regarding its clinical pharmacology, particularly during the induction phase of Methadone Maintenance Treatment (MMT).
- Contrary to previous reports, I found systemic methadone clearance does not increase significantly between induction and steady state phases of MMT, and did not approach the previously reported 3-fold increase. Clinical dose prescription based on the premise of metabolism auto-induction could increase risk of respiratory depression.
- Significant differences between R- and S-methadone pharmacokinetics showed the importance of stereoselective measurement in a clinical situation and significant plasma concentration-effect relationships demonstrated their potential influence on induction pharmacodynamics.
- Small increases in CYP3A4 activity as measured by the Erythromycin Breath Test from Day 1 to Day 40 of MMT were not correlated with changes in methadone clearance. CYP3A4 activities were informative but would be insufficient for use as a sole predictor of methadone clearance during MMT.
- Clinically significant respiratory depression occurred in 20 % of subjects, at times of peak plasma R-methadone concentrations, after reports of withdrawal symptoms at pre-dose sampling times, and irrespective of illicit opioid use. Utilisation of both respiratory rate and blood oxygen saturation measurements provided a good indication of respiratory risk for individuals.

- Although prior opioid use was a strong predictor of continued use during MMT, adoption of a new equation (“abc”) and comprehensive documentation of each individual’s MMT may increase prediction of MMT success.
- Even in light of recent advances in opioid substitution therapies, MMT’s advantages ensure it is still at the forefront of addiction treatment. Careful choice of methodology enabled narrowing of this investigation to those factors most relevant in methadone pharmacology and most responsible for MMT success or failure, and therefore extending previous knowledge of this area. Such data might be utilised to develop a clinically applicable model for MMT, and help provide clients with a safe and uncomplicated transition from heroin use to methadone induction in the future.

Some people dream of great accomplishments...

Others stay awake and get them done!

Successories, Illinois

heroin(e) - anonymous

stayed away my whole life long
for fear of getting burned
till that fateful night in smoke and song
my steadfast head was turned
a drug more potent than any other
an addiction truer than fact
it comes in many shapes and colours
this one in red and black
overcome by temptation
interest outweighs prudence
destined for lust upon creation
the drug welcomes my crudeness
defeated by its savoury smell
my pleasure-lust takes over
as effects take hold i can hardly tell
why i'd ever wish to be sober
i remember well, no need to try
why i found it so appealing
i still recall my first high
with vivid mem'ry of the feeling
for weeks it went on like this
i had to get my fix
and those weeks were nothing short of bliss
my mind played wond'rous tricks
but then one day it all ran out
no drug to fill my veins
and left me alone, empty, in doubt
no heroin(e) to soothe the pains
a year and one half has gone and came
and the addiction still remains
simple mention of the sweet substance' name
sends flashbacks 'cross my brain
and once every now and then
i'll try to get some more
but empty-handed again and again
i'm left hollow to the core

Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopying.

Erin Brooke Morton, 17 January 2007

Acknowledgements

My sincere thanks go to my supervisors Andrew Somogyi, Felix Bochner, and Jason White, my nurses Amanda Mitchell and Charlotte Smith, and co-worker David Foster. I would not have been able to start, let alone complete my project without their help. I'd like to acknowledge my personal funding from the Royal Adelaide Hospital, Dawes Scholarship; the University of Adelaide, Methadone Induction Scholarship; and the NHMRC grant that provided funding for the research itself. Also to be thanked are the wide range of people and places involved. Many thanks go to the staff from Warinilla Clinic, Northern and Southern DASC clinics, with special thanks to Hayley at the DASC library. From the Brian Burdekin Clinic Drs John Foley and Damien Mead, from Willunga's Moore St Clinic: Drs Philip Clarke and Rhys Henning, and from my past employer Hospital Pharmacy Services, Ben Stevenson and Camille Schubert. Within the prisons I would like to thank Drs Chris Holmwood, Chris Clohesy, and Greg Dayman, as well as Jan, Sue, Richard, Fay, Diane, Peter, Brian, Wayne, Joy, Bob, and especially Yasmin. From the RAH my thanks go to Max Bellon and Silvana from Nuclear Medicine, Virginia, Barbara and Kylie from Pharmacy Production, and to all the staff at CMAX. From the university financial department, I thank Genevieve for keeping track of all the cheques. From my own department, for their myriad times of help that enabled me to complete this project, as well as their pleasant company, I would very much like to thank Andy, David N, Aaron, Janet, Pete, Gordon, Mark, and Andrea.

Finally, to Harry and Lyn, the Morton family, and to my own extended family of grandmothers, aunts, uncles and cousins - thank you for your continual support.

Most importantly, I dedicate this thesis with love and thanks:

To my parents Neil and Andrea

You brought me up to believe in myself. To want to prove, if only to myself, that I left no barrier untried. Above all, to have the confidence to quit work and take the plunge.

Thank you.

To my brother Liam

We were blessed with such different talents, skills and interests. And yet at the core we still have so much in common. You breathe life into my creative side, and provide balance in my opposite.

This is for both of us.

To my husband Adam

I could not have done it without you. You anchored me- with your support, smiles and encouragement, and nagging to knuckle down – or lighten up – whenever I needed to hear it. You will always have my love, and my friendship also.

Forever yours.

Publications and presentations in support of this thesis

Somogyi, A.A., Morton, E.B., Bochner, F., White, J.M., Foster, D.J.R., Eichelbaum, M. No alteration in methadone enantiomers disposition between induction and maintenance phases of treatment. *Basic & Clinical Pharmacology & Toxicology* Vol 97, Suppl 1, p65, 2005. Proceedings of the 7th Congress of the European Association for Clinical Pharmacology and Therapeutics, June 25-29, 2005 Poznan, Poland.

Morton, E.B., Somogyi, A.A., Bochner, F., White, J.M., Foster, D.J.R. Disposition of Methadone between Induction and Maintenance Phases of Treatment. ASCEPT/APG Regional Conference, Adelaide, Australia, 26 November 2004

Morton, E.B., Somogyi, A.A., Bochner, F., White, J.M. The Clinical Pharmacology of Methadone Induction. CPT2004, Brisbane, Australia, 1-6 August 2004

Additional publications and presentations associated with the work contained in this thesis

Foster, D.J.R., Morton, E.B., Heinkele, G., Mürdter, T., and Somogyi, A. Stereoselective quantification of methadone and a d_6 -labelled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: Application to a pharmacokinetic study in a methadone maintained subject. *Therapeutic Drug Monitoring* **28** (4), 559-567.

Abbreviations, prefixes and symbols

δ	Delta
κ	Kappa
μ	Mu
σ	Sigma
AAG	α_1 -acid glycoprotein / Alpha-1-acid glycoprotein
<i>ABCB1</i>	Multi-drug resistance gene (current name)
AEs	Adverse Effects
AIDS	Acquired Immuno-deficiency Syndrome
AIHW	Australian Institute of Health and Welfare
Ala	Alanine
ALT	Alanine transaminase
Asn	Asparagine
Asp	Aspartic acid
ASPD	Antisocial Personality Disorder
AST	Aspartate aminotransferase-serum
AUC	Area Under the plasma concentration-time Curve
BD	Becton Dickinson
C	Cytosine
Ca^{2+}	Calcium Ion
CaMKII	Ca^{2+} /calmodulin-dependent protein kinase II
cAMP	Adenosine 3',5'-cyclic monophosphate
CER	Percentage of ^{14}C -Erythromycin dose released per minute as labelled carbon dioxide
$\text{CER}_{20\text{min}}$	CER at, for example, 20 minutes after ^{14}C -Erythromycin dose
CLND	Chemiluminescent-nitrogen detector
CoA	Coenzyme A
CNS	Central Nervous System
CP	Cold Pressor (Test)
CV	Coefficient of Variation
CYP450	Cytochrome P450 enzymes
CYP3A4/CYP2D6 etc	Cytochrome P450 3A4/2D6 etc
<i>CYP2D6</i>	Cytochrome P450 2D6 gene
d0	Unlabelled methadone
d3	Deuterium labelled methadone (3 deuterium atoms)

d6	Deuterium labelled methadone (6 deuterium atoms)
D*	Day * of MMT
DAMGO	[D-Ala ² ,N-MePhe ⁴ ,Gly-ol ⁵] enkephalin
DASC	Drug & Alcohol Services Council
DCS	Department of Correctional Services
DNA	Deoxyribonucleic Acid
DPHM	Diphenhydramine
dpm	Decay per minute
<i>DRD2</i>	Dopamine <i>D2</i> Receptor
DSM-III-R	Borderline Personality Disorder
EBT	Erythromycin Breath Test
EDDP	2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine
EMDP	2-ethyl-5-methyl-3,3-diphenpyrroline
EUT	Erythromycin Urine Test
GABA	Gamma Aminobutyric Acid
GC-MS	Gas Chromatography – Mass Spectrometry
GPCR	G-protein coupled receptor
GRK	G-protein coupled receptor kinases
HIV	Human Immunodeficiency Virus
HPLC	High Performance Liquid Chromatography
HQC	High Concentration Quality Control
IC ₅₀	Concentration for 50 % inhibition
INR	International Normalized Ratio
IS	Internal Standard
iv	Intravenous
K ⁺	Potassium Ion
LAAM	<i>Levo-α-acetylmethadol</i> / <i>Levo-alpha-acetylmethadol</i>
LC-MS	Liquid Chromatography – Mass Spectrometry
LOQ	Limit of Quantification
LQC	Low Concentration Quality Control
MAPK	Mitogen-activated protein kinase
<i>MDR1</i>	Multi-drug resistance gene (old name)
MIA-	Methadone Induction Study A subject
MIB-	Methadone Induction Study B subject
MMT	Methadone Maintenance Treatment

MOP	Mu Opioid (Peptide) Receptor
MQC	Medium Concentration Quality Control
MSC	Methadone Symptoms Checklist
MSCWYN	Methadone Symptoms Checklist –Withdrawal subscale, categorical scoring
NAS	Neonatal Abstinence Syndrome
NMDA	N-methyl-D-aspartate
NTS	Tractus solitarius
<i>OPRM1</i>	Mu Opioid Receptor Gene
ORM	Orosomucoid
PAR	Peak Area Ratio
PD	Pharmacodynamics
PEF	Peak Expiratory Flow
P-gp	P-glycoprotein
PhD	Doctorate of Philosophy
PK	Pharmacokinetics
PKA	Cyclic AMP-dependent protein kinase (protein kinase A)
PKC	Protein Kinase C
POMS	Profile of Mood States
QC	Quality Control
r^2	Coefficient of Determination
R-	Right
Rac-	Racemic
RAH	Royal Adelaide Hospital
RIA	Radioimmunoassay
RNA	Ribonucleic Acid
RP-HPLC	Reverse-Phase High Performance Liquid Chromatography
SA	South Australia
SAEs	Serious Adverse Effects
SAVIVE	South Australia Voice for IV Education
S	Sinister
S1/S2	Standard number 1/ Standard number 2
SD	Standard Deviation
SNP	Single Nucleotide Polymorphism
SROM	Slow Release Oral Morphine
Thy	Thymine

T_{\max}	Time of Maximum labelled carbon dioxide exhalation
TH	Alpha-tocopherol
TMD	Total Mood Disturbance
TQ	Alpha-tocopherolquinone
UCR	Urinary Cortisol Ratio
US/USA	United States of America
UV	Ultraviolet
UV-HPLC	High Performance Liquid Chromatography with Ultraviolet Detection
VAS	Visual Analogue Scale
WHO	World Health Organisation